Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome

MM Asfari et al. aimed to evaluate the association between polycystic ovarian syndrome and NAFLD using a large national database. Adult female patients (≥18 years) with polycystic ovarian syndrome using the National Inpatient Sample database between 2002 and 2014. The control group included...
Read MoreAssociation of non-alcoholic fatty liver disease and polycystic ovarian syndrome

The changing global epidemiology of hepatocellular carcinoma

Hepatocellular carcinoma is the fifth and ninth most commonly diagnosed cancer in men and women, respectively, and the fourth leading cause of cancer mortality worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly non-alcoholic fatty liver disease) and exposure...
Read MoreThe changing global epidemiology of hepatocellular carcinoma

Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes

Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). These associations could be mediated by insulin resistance.However, the relationships among these metabolites, insulin resistance and NAFLD have...
Read MoreTrimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes

Non-alcoholic fatty liver disease and alcohol-related liver disease: Two intertwined entities

In their review, F. Idalsoaga et al. (Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile) aim to summarise current data on the overlapping pathophysiology of NAFLD and alcohol-related fatty liver disease, the available information on alcohol consumption in patients with NAFLD...
Read MoreNon-alcoholic fatty liver disease and alcohol-related liver disease: Two intertwined entities

Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease

anifibranor is a moderately potent and well-balanced modulator of the three PPAR isotypes and has a good safety profile. Beneficial effects of lanifibranor on NASH histology, including reduced fibrosis, were confirmed recently in a preclinical model of NASH and fibrosis (choline-deficient amino acid-defined HFD mouse model)...
Read MorePeroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease

Automated thermal imaging for the detection of fatty liver disease

NAFLD comprises a spectrum of progressive liver pathologies, ranging from simple steatosis to NASH, fibrosis, and cirrhosis. A liver biopsy is currently required to stratify high‐risk patients. Predicting the degree of liver inflammation and fibrosis using non‐invasive tests remains challenging...
Read MoreAutomated thermal imaging for the detection of fatty liver disease

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease

Physical inactivity and sedentary lifestyle have contributed to the epidemic of obesity and NAFLD. Moreover, NAFLD and sarcopenia have similar pathophysiological profiles. ZM Younossi et al. assessed the association between physical activity, NAFLD, and sarcopenia, and their contributions to mortality, using data from the National Health and Nutrition...
Read MoreContribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease

Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

The results of randomized controlled trials (RCTs) investigating supplemental vitamin D on aminotransferases and cardio-metabolic risk factors in subjects with NAFLD have been inconsistent. A meta-analysis of randomized controlled trials by XF Guo et al. (Institute of Nutrition & Health, Qingdao University...
Read MoreVitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

NAFLD and type 2 diabetes are closely associated phenomena. In contrast to the knowledge about NAFLD and type 2 diabetes, there are limited and inconsistent data on NAFLD prevalence in patients with type 1 diabetes mellitus. Type 1 diabetes and type 2 diabetes show major pathophysiological differences but share certain...
Read MorePrevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

Non-alcoholic fatty liver disease modifies serum gamma-glutamyl transferase in cigarette smokers

Serum gamma-glutamyl transferase (GGT) is a marker of oxidative stress, associated with increased cardiovascular risk. The impact of smoking on oxidative stress may be aggravated in individuals with NAFLD. ET Oni et al. (Cardiology Division, Heart and Vascular Institute, Einstein Medical Center, Philadelphia, PA, USA) aimed to...
Read MoreNon-alcoholic fatty liver disease modifies serum gamma-glutamyl transferase in cigarette smokers

Fatty Liver Index: A Hypertension Predictor in a South Korean Cohort

Although there can be common pathogenic mechanisms for NAFLD and hypertension associated with the development of cardiovascular diseases, little data are showing the association between NAFLD and hypertension in a large-scale cohort study. JH Roh et al. (department of cardiology in internal medicine, Chungnam National University Hospital, Daejeon, Korea)...

Read MoreFatty Liver Index: A Hypertension Predictor in a South Korean Cohort